Active Ingredient(s): Selpercatinib
FDA Approved: * May 8, 2020
Pharm Company: * LOXO ONCOLOGY INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Retevmo Overview

Selpercatinib, sold under the brand name Retevmo, is a medication for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET or "rearranged during transfection").[3][1] It is taken by mouth.[1] The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood ...

Read more Retevmo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Retevmo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 40mg, 80mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Retevmo: (2 results)

Sorted by National Drug Code
  • 0002-2980 Retevmo 80 mg Oral Capsule by Eli Lilly and Company
  • 0002-3977 Retevmo 40 mg Oral Capsule by Eli Lilly and Company

Other drugs which contain Selpercatinib or a similar ingredient: (1 result)